BioWorld

July 15, 2008

Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece

Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) in up-front, development and sales-related milestones. (BioWorld Today) Read More

Proximagen Stands to Get $232M in Deal for Parkinson's Drug

Amgen Issues Positive Results; Settles Ortho Case for $200M

Cardiome Moving Toward Pivotal Studies of Oral Vernakalant in AF

Neurogen Halts Dosing of Adipiplon in Insomnia

OncoGenex Gets SPA for Phase III HRPC Trial

Pacific's $100M Fundraising to Fund Sequencing Tool

Genta Shares Soar as FDA Sets Genasense Action Date

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...